Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$4.26-0.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · IRWD
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||
| Revenues | 389.3 | 296.2 | 351.4 | 442.7 | 410.6 | 413.8 | 389.5 | 428.4 | 346.6 | 298.3 | 274.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 298.3 | 274.0 |
| Cost of Revenues | — | — | — | — | — | — | 3.1 | 23.9 | 32.8 | 19.1 | 1.9 |
| Operating Expenses & Income | |||||||||||
| Selling, General & Admin | 64.5 | 82.3 | 144.3 | 158.3 | 116.0 | 111.1 | 140.0 | 172.5 | 219.7 | 231.2 | 173.3 |
| R&D Expenses | 88.7 | 95.1 | 111.4 | 1,100.0 | 44.3 | 70.4 | 88.1 | 115.0 | 101.1 | 88.1 | 139.5 |
| Operating Income | 234.2 | 98.5 | 93.1 | (945.4) | 250.3 | 232.3 | 142.9 | 120.1 | (150.7) | (15.4) | (51.9) |
| Earnings from Continuing Operations | |||||||||||
| Interest Expense | — | 32.7 | 33.0 | 21.6 | 7.6 | 31.2 | 29.5 | 36.6 | 37.7 | 36.4 | 39.2 |
| Other Non-Operating Income / Expenses | (26.8) | (28.5) | (27.9) | (2.6) | 2.1 | (31.6) | (34.1) | (61.2) | (43.5) | (39.6) | (29.8) |
| EBT, Incl. Unusual Items | 207.4 | 70.0 | 65.2 | (948.1) | 252.4 | 200.7 | 108.9 | — | — | — | — |
| Income Tax Expense | 77.5 | 46.0 | 64.3 | 83.5 | 77.4 | (327.8) | 2.7 | 0.0 | 0.0 | 0.0 | 0.0 |
| Earnings from Continuing Operations | — | — | — | — | — | 528.4 | 106.2 | 58.9 | — | — | — |
| Net Income | |||||||||||
| Minority Interest | — | — | — | (29.3) | — | — | — | — | — | — | — |
| Net Income | 129.9 | 24.0 | 0.9 | (1,031.6) | 175.1 | 528.4 | 106.2 | 21.5 | (282.4) | (116.9) | (81.7) |
| Per Share | |||||||||||
| Basic EPS | 0.79 | 0.15 | 0.01 | (6.45) | 1.13 | 3.26 | 0.67 | 0.14 | — | — | — |
| Diluted EPS | 0.78 | 0.15 | 0.01 | (6.45) | 0.96 | 3.21 | 0.66 | 0.14 | — | — | — |
| Revenue per Share | 2.33 | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 164.4 | 161.8 | 159.1 | 155.4 | 154.4 | 162.2 | 159.4 | — | — | — | — |
| Diluted Weighted Avg Shares | 167.2 | 163.0 | 160.1 | 155.4 | 186.3 | 164.4 | 160.7 | — | — | — | — |
| Supplemental | |||||||||||
| EBITDA | — | 99.6 | 94.3 | (944.2) | 251.7 | 233.8 | 145.2 | 125.7 | (146.8) | (9.0) | (41.6) |
| EBIT | 234.2 | 98.5 | 93.1 | (945.4) | 250.3 | 232.3 | 142.9 | 120.1 | (150.7) | (15.4) | (51.9) |
| Effective Tax Rate | 37.4% | — | — | -8.8% | 30.6% | -163.4% | 2.5% | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.